Combination drug therapy for advanced fibrolamellar carcinoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of two drugs—DRP-104 and durvalumab—to see if they can shrink or slow advanced fibrolamellar carcinoma, a rare liver cancer. It is for patients whose cancer has gotten worse even after immunotherapy treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a rare liver cancer called fibrolamellar carcinoma that has spread or cannot be removed with surgery
- Your tumor must have a specific genetic change called the DNAJB1-PRKACA fusion
- Your cancer must have gotten worse during or after prior immunotherapy treatment
- You must be at least 12 years old, or 40 kg if under 18
- You need to be generally able to care for yourself (ECOG performance status 0, 1, or 2)
- You must agree to give blood and tissue samples for research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new vaccine (a shot that may help your immune system attack cancer cells) combined with a glutamine-blocking drug (DRP-104) and two immunotherapy drugs (nivolumab and ipilimumab) for advanced fibrolamellar carcinoma. It aims to see if this combination can shrink tumors or slow their growth.
This Phase 1 trial tests a personalized peptide vaccine (targeting the DNAJB1-PRKACA fusion) combined with immunotherapy drugs to treat fibrolamellar hepatocellular carcinoma (FLC) or other eligible non-FLC cancers with the same gene fusion. It aims to see whether this immune-based treatment can shrink tumors and improve outcomes safely.
This trial tests a new drug combination for liver cancer that has progressed after standard treatment. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a patient-specific vaccine for people who have a rare type of liver cancer called fibrolamellar hepatocellular carcinoma (FL-HCC), or another cancer with the same genetic change. The vaccine is given after the cancer has been completely removed or treated, and it aims to teach your immune system to recognize and destroy any cancer cells that might be left.
This Phase 1/2 trial tests whether nivolumab combined with fluorouracil and interferon alpha can treat fibrolamellar liver cancer that cannot be safely removed with surgery. It aims to shrink or control the cancer and to see how safe the combination is.
This trial tests a combination of two immunotherapy drugs, TACE (a procedure to block blood flow to tumors), and lenvatinib (a targeted therapy) for people with liver cancer that has not responded to initial treatment. It aims to see if this combination can help shrink tumors or slow cancer growth.
Hear when a new Fibrolamellar Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.